All In Biotech

Drug Trial Radar · NCT07570082

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

May 28, 2026

Primary completion

Jun 30, 2026

Study completion Jul 30, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • AtumelnantDrug

    Atumelnant, tablets

  • CarbamazepineDrug

    CYP3A4 inducer

  • MidazolamDrug

    CYP3A4 substrate

  • DigoxinDrug

    P-gp substrate

  • MetforminDrug

    MATE1/2-K substrate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Pharmacokinetics (AUC 0-last)Time frame: Up to Day 34
  2. Cohort 1: Pharmacokinetics (AUC 0-inf)Time frame: Up to Day 34
  3. Cohort 1: Pharmacokinetics (Cmax)Time frame: Up to Day 34
  4. Cohort 2: Pharmacokinetics (AUC 0-last)Time frame: Up to Day 21
  5. Cohort 2: Pharmacokinetics (AUC 0-inf)Time frame: Up to Day 21
  6. Cohort 2: Pharmacokinetics (Cmax)Time frame: Up to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.